Blue Jet Healthcare Limited conducted its Q3FY26 earnings conference call on February 13, 2026, providing comprehensive updates on financial performance, strategic initiatives, and future growth plans. The call was moderated by Ernst & Young and featured key management personnel including Managing Director Shiven Arora, COO V.K. Singh, CFO Ganesh Karuppannan, and Deputy CFO Sanjay Sinha.

Strategic Business Updates and Expansion Plans

The management announced several significant strategic initiatives during the earnings call. The groundbreaking ceremony for the Vizag Greenfield project is scheduled for February 2026, representing a pivotal growth platform with a total investment plan of ₹1,000 crores over three to four years. Phase-1 will establish dedicated capacity for API and intermediates focused on new products aligned with customer requirements.

The company has secured lease space for R&D activities in Hyderabad, with development work expected to commence from Q3 FY27. This expansion will focus on emerging technologies including intermediates for GLP-1s, peptide chemistry, and bio-catalysis.

Supply Chain Realignment and Product Pipeline

Management addressed the supply chain realignment affecting their pharmaceutical intermediates business, particularly the Bempedoic acid molecule. V.K. Singh, COO, explained that the realignment involves both channel inventory destocking and supply chain restructuring, which may take a couple of quarters to normalize completely. Despite current challenges, the end molecule continues showing mid-level double-digit growth with new market entries including Japan.

The company is tracking 20 active RFPs, with six high-conviction phase-III programs including GLP-1 candidates and one contrast media NCE. Two commercial products may evolve into strategic lateral entries with dedicated capacity planning.

Contrast Media Business Development

The contrast media segment showed mixed performance with management highlighting three key needle movers. The advanced intermediate for existing products is currently under validation with five-year capacity readiness. The NCE intermediate has performed well over the past 12 months following the December 2024 line commencement.

Financial Performance Analysis

Deputy CFO Sanjay Sinha provided detailed financial metrics during the call. Revenue from operations decreased 40% year-on-year, while EBITDA decreased 62% and PAT decreased 39%. Quarter-on-quarter performance showed revenue increase of 16%, though EBITDA and PAT declined due to product mix changes and one-time impacts.

Operational Excellence and Sustainability

The company continues embedding sustainability into operations with 70% of power consumption now met through wind and solar sources. Blue Jet Healthcare was recently recognized by CII with the National Award for Excellence in Energy Management. The company has built a dedicated process excellence department supported by strong additions in engineering, quality, and supply chain management.

Future Outlook and Investment Strategy

Management expressed confidence in FY27 outlook based on capacity utilizations and customer orders for major product lines. The Vizag CAPEX is specifically designed for projects with confirmed customer demand rather than speculative capacity creation. The company maintains a debt-free status with ₹410 crores cash as of December 2025, providing multiple funding options for the announced investment program including internal accruals, debt markets, or capital markets.

Blue Jet Healthcare Limited has scheduled an analyst and investor conference call to discuss its financial performance for the third quarter and nine months of fiscal year 2026. The pharmaceutical company announced the earnings call through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Earnings Call Details

The conference call is scheduled to discuss the company's unaudited standalone financial results for the quarter and nine months ended December 31, 2025. Company Secretary and Compliance Officer Sweta Poddar signed the regulatory intimation on February 6, 2026.

Management Participation

The earnings call will feature key members of Blue Jet Healthcare's senior management team who will present the financial results and address questions from analysts and investors.

Company Profile

Blue Jet Healthcare Limited operates as a specialty pharmaceutical and healthcare ingredient company under a contract development and manufacturing organization (CDMO) business model. The company has developed specialized chemistry capabilities in two key areas: contrast media intermediates and high-intensity sweeteners.

The company has established long-term relationships with innovator and multinational generic pharmaceutical companies, supported by multi-year contracts. Blue Jet Healthcare supplies critical starting intermediates and advanced intermediates to three of the world's largest contrast media manufacturers, including GE Healthcare, Guerbet, and Bracco. Additionally, the company provides high-intensity sweeteners to multinational companies such as Colgate Palmolive India Limited and Unilever.

Contact Information

For further details regarding the earnings call, stakeholders can contact Company Secretary Sweta Poddar at companysecretary@bluejethealthcare.com . Investor relations support is provided by EY Investor Relations through Diwakar Pingle and Kunal Bhoite. Participants are advised to dial in 10 minutes before the scheduled call time.